Patterns of care and survival outcomes for laryngeal small cell cancer.
Adult
Aged
Aged, 80 and over
Carcinoma, Small Cell
/ mortality
Chemoradiotherapy
Databases, Factual
Female
Humans
Kaplan-Meier Estimate
Laryngeal Neoplasms
/ mortality
Male
Middle Aged
Practice Patterns, Physicians'
Proportional Hazards Models
Survival Rate
Treatment Outcome
United States
Young Adult
chemotherapy
head and neck
neuroendocrine cancer
radiation
surgery
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
15
04
2018
revised:
19
07
2018
accepted:
21
09
2018
entrez:
21
2
2019
pubmed:
21
2
2019
medline:
8
10
2020
Statut:
ppublish
Résumé
To determine practice patterns and outcomes of laryngeal small cell cancer (LSCC) across the United States. Patients with LSCC were identified in the National Cancer Database. Overall survival (OS) was compared with Kaplan-Meier analysis and Cox regression. From 2004 to 2014, the 5-year OS for early stage (n = 47), locally advanced stage (n = 133), and metastatic disease (n = 53) was 34%, 26%, and 9%, respectively. Chemoradiation was given in 66% of cases. Chemotherapy was less likely given in early stage disease (P = .001), and definitive radiation was less likely given in metastatic disease (P < .001). Definitive radiation improved median OS in locally advanced LSCC (20 vs. 7 months, log-rank P = .04). In multivariable modeling, radiation dose ≥40 Gy was associated with better OS (P < .001). Chemoradiation was the most common practice for treating locally advanced LSCC, and radiation dose ≥40 Gy was associated with improved OS.
Sections du résumé
BACKGROUND
To determine practice patterns and outcomes of laryngeal small cell cancer (LSCC) across the United States.
METHODS
Patients with LSCC were identified in the National Cancer Database. Overall survival (OS) was compared with Kaplan-Meier analysis and Cox regression.
RESULTS
From 2004 to 2014, the 5-year OS for early stage (n = 47), locally advanced stage (n = 133), and metastatic disease (n = 53) was 34%, 26%, and 9%, respectively. Chemoradiation was given in 66% of cases. Chemotherapy was less likely given in early stage disease (P = .001), and definitive radiation was less likely given in metastatic disease (P < .001). Definitive radiation improved median OS in locally advanced LSCC (20 vs. 7 months, log-rank P = .04). In multivariable modeling, radiation dose ≥40 Gy was associated with better OS (P < .001).
CONCLUSION
Chemoradiation was the most common practice for treating locally advanced LSCC, and radiation dose ≥40 Gy was associated with improved OS.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
722-729Informations de copyright
© 2018 Wiley Periodicals, Inc.